Bridge Funding Award Overview:
The Rivkin Center for Ovarian Cancer is announcing funds for up to one Bridge Funding Award based on scientific merit. The purpose of Bridge Funding is to allow researchers to produce data needed to substantiate their proposal resubmission to federal funding agencies for a promising new research project. The Rivkin Center provides interim funding of up to $30,000 to researchers who have submitted an R01, R21, K08, K23, or K99 proposal to the National Institutes of Health (NIH) or an original proposal to the Department of Defense (DoD) pertaining to ovarian cancer and who have not received, but were close to, a fundable score. Investigator-initiated projects in all areas of ovarian cancer research are eligible. Special consideration will be given to research that has clinical applicability. Funds are for direct costs only; institutional overhead and indirect costs will not be included in the award.

Applicants may budget for salary support, materials, supplies, consumables, and other expenses as justified. Budget and budget justification must be included with the application.

Eligibility:
Investigators at all levels are encouraged to apply. Unfunded first submission NIH R01, R21, K08, K23, and K99 proposals (no A1 or A2 proposals) as well as original DoD proposals are eligible for consideration. NIH proposals must have scored in the 19th percentile or lower, and DoD proposals must have scored less than 1.9. Proposals must have received their agency score within the past 9 months. Proposals must require at least six months of additional research work prior to resubmission.

Requirements upon funding:
A final scientific report, final financial report, and lay abstract must be provided within 90 days after the completion of the funding period. The outcome of the resubmission must also be reported to the Rivkin Center.

Application Format and Instructions:
Applicants should submit a proposal application to the Rivkin Center via proposalCENTRAL including applicant/PI and institution contact information, scientific proposal summary, budget information, a copy of the original proposal to NIH or DoD, a copy of the reviewers’ Summary Statement evaluating the proposal submitted to NIH or DoD together with responses to the Statement’s critiques. Additional materials (e.g. published papers, letters of support) will not be considered. The scientific proposal summary should include three components: (A) Abstract describing the rationale, specific aims, and general methodology of the project (not more than 1 page); (B) Explanation of the potential impact of this research on the understanding, prevention, diagnosis, and/or treatment of ovarian cancer (not more than 1 page); (C) Discussion of how the funds from the Rivkin Center will be used to address the score-driving issues raised in the Summary Statement from the reviewers (not more than 1 page). Be sure to include the expected date of resubmission to NIH or of new submission to DoD.

Application Submission:
All application materials should be submitted through proposalCENTRAL by the application due date (May 1, 2020, 5PM Eastern Time). Applicants who do not already have an account in proposalCENTRAL must register (Link for site) for an account prior to beginning application. Once completed, the application must be validated to ensure all materials have been submitted. Signature pages must be printed for a wet signature (not an electronic signature) from the named institutional official and then uploaded to proposalCENTRAL.

More Information:
Visit proposalCENTRAL.com or www.rivkin.org for the full "Bridge Funding Award Guidelines." Questions may be directed to Kiran.Dhillon@swedish.org.